This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ASM journals
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Caron, F
Right arrow Articles by Carbon, C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Caron, F
Right arrow Articles by Carbon, C

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1992 December; 36(12): 2611-2616

Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium.

F Caron, M D Kitzis, L Gutmann, A C Cremieux, B Maziere, J M Vallois, A Saleh-Mghir, J F Lemeland and C Carbon

Groupe de Recherche en Infections Expérimentales, Hôpital Charles Nicolle, Rouen, France.

ABSTRACT

Using an experimental endocarditis model, we studied the activity of daptomycin used alone or in combination with gentamicin against an Enterococcus faecium strain that was highly resistant to glycopeptides and susceptible to gentamicin. In vitro, the MIC of daptomycin was 1 micrograms/ml. In vivo, daptomycin appeared to be effective only when it was used in a high-dose regimen, i.e., 12 mg/kg of body weight every 8 h (-2.5 log10 CFU/g versus controls; P < 0.05), particularly when it was combined with gentamicin (-5.0 log10 CFU/g versus controls; P < 0.01). Since the distribution of daptomycin into cardiac vegetations, as evaluated by autoradiography, appeared to be homogeneous, the poor in vivo activity of daptomycin was considered to be related to its high degree of protein binding, as suggested by killing curves studies. Since the MIC of teicoplanin for the vancomycin-resistant E. faecium strain used in the study was only 64 micrograms/ml and since an in vitro synergy between teicoplanin at high dose and gentamicin was observed, a high-dose regimen of teicoplanin, i.e., 40 mg/kg every 12 h, was also assessed in vivo. This treatment provided marginal activity only when it was combined with gentamicin (-2.3 log10 CFU/g versus controls; P < 0.05). These results suggest that the levels of daptomycin or teicoplanin in serum required to cure experimental endocarditis caused by a highly glycopeptide-resistant strain of E. faecium would not be achievable in humans.

Antimicrob Agents Chemother. 1992 December; 36(12): 2611-2616




This article has been cited by other articles:

  • Levine, D. P. (2008). Clinical experience with daptomycin: bacteraemia and endocarditis. J Antimicrob Chemother 62: iii35-iii39 [Abstract] [Full Text]  
  • Marco, F., Garcia de la Maria, C., Armero, Y., Amat, E., Soy, D., Moreno, A., del Rio, A., Almela, M., Mestres, C. A., Gatell, J. M., Jimenez de Anta, M. T., Miro, J. M., for the Hospital Clinic Experimental Endocarditis, (2008). Daptomycin Is Effective in Treatment of Experimental Endocarditis Due to Methicillin-Resistant and Glycopeptide-Intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 52: 2538-2543 [Abstract] [Full Text]  
  • Falagas, M. E., Giannopoulou, K. P., Ntziora, F., Vardakas, K. Z. (2007). Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence. J Antimicrob Chemother 60: 7-19 [Abstract] [Full Text]  
  • Vouillamoz, J., Moreillon, P., Giddey, M., Entenza, J. M. (2006). Efficacy of daptomycin in the treatment of experimental endocarditis due to susceptible and multidrug-resistant enterococci. J Antimicrob Chemother 58: 1208-1214 [Abstract] [Full Text]  
  • Pankey, G., Ashcraft, D., Patel, N. (2005). In Vitro Synergy of Daptomycin plus Rifampin against Enterococcus faecium Resistant to both Linezolid and Vancomycin. Antimicrob. Agents Chemother. 49: 5166-5168 [Abstract] [Full Text]  
  • Shah, M., Murillo, J. L (2005). Successful Treatment of Corynebacterium striatum Endocarditis with Daptomycin plus Rifampin. The Annals of Pharmacotherapy 39: 1741-1743 [Abstract] [Full Text]  
  • Tsuji, B. T., Rybak, M. J. (2005). Short-Course Gentamicin in Combination with Daptomycin or Vancomycin against Staphylococcus aureus in an In Vitro Pharmacodynamic Model with Simulated Endocardial Vegetations. Antimicrob. Agents Chemother. 49: 2735-2745 [Abstract] [Full Text]  
  • Akins, R. L., Rybak, M. J. (2001). Bactericidal Activities of Two Daptomycin Regimens against Clinical Strains of Glycopeptide Intermediate-Resistant Staphylococcus aureus, Vancomycin-Resistant Enterococcus faecium, and Methicillin-Resistant Staphylococcus aureus Isolates in an In Vitro Pharmacodynamic Model with Simulated Endocardial Vegetations. Antimicrob. Agents Chemother. 45: 454-459 [Abstract] [Full Text]  
  • Souli, M., Thauvin-Eliopoulos, C., Eliopoulos, G. M. (2000). In Vivo Activities of Evernimicin (SCH 27899) against Vancomycin-Susceptible and Vancomycin-Resistant Enterococci in Experimental Endocarditis. Antimicrob. Agents Chemother. 44: 2733-2739 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»